Training activity information
Details
Analyse and interpret results for targeted genomic dosage analysis associated with paediatric disorders, as examples:
- SMA
- DMD/BMD
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What specific knowledge is essential before analysing and interpreting results for SMA and DMD/BMD dosage analysis? Consider the genetic mechanisms underlying these conditions, the principles of dosage analysis techniques, and the expected patterns of results.
- What preparatory steps will you take for this activity? Will you consult resources on SMA and DMD/BMD genetics and testing methodologies? Will you discuss the interpretation of dosage analysis results with experienced colleagues?
- What potential difficulties might arise during the analysis and interpretation of these results? Consider challenges such as identifying the precise breakpoints of deletions or duplications, or interpreting results in the context of incomplete penetrance. How do you plan to address these difficulties?
- What specific knowledge is essential before analysing and interpreting results for SMA and DMD/BMD dosage analysis? Consider the genetic mechanisms underlying these conditions, the principles of dosage analysis techniques, and the expected patterns of results.
- What preparatory steps will you take for this activity? Will you consult resources on SMA and DMD/BMD genetics and testing methodologies? Will you discuss the interpretation of dosage analysis results with experienced colleagues?
- What potential difficulties might arise during the analysis and interpretation of these results? Consider challenges such as identifying the precise breakpoints of deletions or duplications, or interpreting results in the context of incomplete penetrance. How do you plan to address these difficulties?
In action
- What testing strategies are being used for SMA and DMD/BMD analysis? What specific regions or genes are you focusing on, and why?
- What key decisions are you making as you assess the copy number of genes like SMN1, SMN2, and DMD? How are you determining the presence or absence of deletions or duplications?
- What are the limitations of the current testing methods?
- What are the key considerations when completing dosage analysis interpretation?
- How do the results from analysis relate to your understanding of different phenotypes seen in these conditions?
- If your initial analysis yields ambiguous or unclear results, what alternative strategies could you employ to clarify the findings? Could you review quality control metrics or consider alternative analysis parameters?
- Do you need to seek immediate clarification or advice on any unusual patterns or results you are observing that deviate from expected findings?
- Are you ensuring that your interpretation aligns with the clinical information provided in the referral and considers the potential implications of different dosage alterations for diagnosis and prognosis?
On action
- Summarise key aspects of testing strategy and analysis performed. e.g. genes analysed, results and interpretations.
- What specific skills or knowledge did you gain regarding the genomic regions and common dosage alterations involved in SMA and DMD/BMD?
- What unexpected challenges or successes did you encounter—such as interpreting complex dosage patterns or determining carrier status—and how did adapting your approach lead to a more accurate interpretation?
- How will these improved interpretative skills contribute to your ability to diagnose these paediatric disorders in your future practice?
- What specific areas for development have you identified, such as improving your understanding of SMN2 copy numbers in SMA, correlating DMD deletions/duplications with phenotypes, or adopting new strategies for reviewing quality control metrics and borderline results?
- What concrete ‘next steps’ will you take to consolidate your learning, such as systematically reviewing national guidelines for SMA and DMD/BMD testing or discussing challenging cases with a senior colleague?
- What support or resources are necessary for your continued development, such as gaining access to specific genomic databases or receiving training on new dosage analysis platforms?
Beyond action
- Have you revisited the experiences of analysing and interpreting targeted genomic dosage analysis for SMA and DMD/BMD? Have any national recommendations for testing or reporting in SMA or DMD/BMD changed since you completed this training activity?
- Compare these experiences with other training activities involving the interpretation of quantitative genomic data, such as copy number variant (CNV) analysis. What similarities and differences have you noticed in the analytical and interpretative processes?
- Revisit your reflections on this training activity and others related to specific genetic disorders. What overarching themes or learning points have emerged regarding the application of targeted genomic testing in paediatrics?
- Discuss any challenging cases or unexpected findings from these dosage analyses with colleagues. Has their perspective offered any new insights or alternative interpretations?
- Recognise how your initial experiences with SMA and DMD/BMD dosage analysis have contributed to your broader understanding of gene dosage effects in genetic disorders. How has this foundational knowledge influenced your approach to interpreting results for other conditions?
- How have you applied your skills in dosage analysis in subsequent work or training activities? Have you become more confident in identifying potential pitfalls or limitations of these techniques?
- Can you now more effectively explain the principles behind dosage analysis and the clinical significance of different results?
- Identify specific areas for continued development, such as keeping abreast of new technologies for dosage analysis or expanding your knowledge of rare dosage-related disorders.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Perform targeted analysis for patients referred with paediatric conditions. |
| # 5 |
Outcome
Interpret and report genomic testing relevant to paediatric conditions, including appropriate recommendations for patient management. |